Clinical trial
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) +…
NCT00063401 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00063401 |
|---|---|
| Title | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
| Official title | A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms |
| Intervention type | Biological, Drug |
| Interventions | Cetuximab:, Paclitaxel, Carboplatin |
| Enrollment | 39 |
| Start date | Sep 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Jun 27, 2003 |
| Last update posted | Apr 8, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: